An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer

• DOI: 10.1016/j.xcrm.2022.100525
• Publication Date: 2022-02-15T17:08:28Z
• Authors: Brett E. Johnson; Allison L. Creason; Jayne M. Stommel; Jamie M. Keck; Swapnil Parmar; Courtney B. Betts; Aurora Blucher; Christopher Boniface; Elmar Bucher; Erik Burlingame; Todd Camp; Koei Chin; Jennifer Eng; Joseph Estabrook; Heidi S. Feiler; Michael B. Heskett; Zhi Hu; Annette Kolodzie; Ben L. Kong; Marilyne Labrie; Jinho Lee; Patrick Leyshock; Souraya Mitri; Janice Patterson; Jessica L. Riesterer; Shamilene Sivagnanam; Julia Somers; Damir Sudar; Guillaume Thibault; Benjamin R. Weeder; Christina Zheng; Xiaolin Nan; Reid F. Thompson; Laura M. Heiser; Paul T. Spellman; George Thomas; Emek Demir; Young Hwan Chang; Lisa M. Coussens; Alexander R. Guim...; Christopher Corless; Jeremy Goecks; Raymond Bergan; Zahi Mitri; Gordon B. Mills; Joe W. Gray
• Keywords: Tumour heterogeneity

Mechanisms of therapeutic resistance and vulnerability evolve in metastatic cancers as tumor cells extrinsic microenvironmental influences change during treatment. To support the development methods for identifying these mechanisms individual people, here we present an omic multidimensional spatial (OMS) atlas generated from four serial biopsies with breast cancer 3.5 years therapy. This resource links detailed, longitudinal clinical metadata that includes treatment times doses, anatomic imaging, blood-based response measurements to exploratory analyses, which comprehensive DNA, RNA, protein profiles; images multiplexed immunostaining; 2- 3-dimensional scanning electron micrographs. These data report aspects heterogeneity evolution genome, signaling pathways, immune microenvironment, cellular composition organization, ultrastructure. We illustrative examples how integrative analyses reveal potential suggest novel vulnerabilities.